Initiated Phase 1 clinical trial in 10 patients to assess both safety and clinical efficacy. First two sites, Mayo Clinic and Univ of Michigan, have been activated in July and August of 2023 to recruit patients.
FDA’s approval of HRGN’s first IND is an extremely important milestone for HRGN as it will transition Biostage into a clinical stage company
Recent Press
Regenerations Ahead
Regenerations Ahead
Esophageal Atresia
Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective
Treatment
Approximately 1 in 4,000 babies, in the US alone, are born
with this congenital defect. Find out how HRGN is working to
answer this unmet medical need.
Esophageal Atresia
Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective
Treatment
Approximately 1 in 4,000 babies, in the US alone, are born
with this congenital defect. Find out how HRGN is working to
answer this unmet medical need.
Esophageal Atresia
Esophageal Atresia:
A Life-Threatening Condition
that Demands Effective
Treatment
Approximately 1 in 4,000 babies, in the US alone, are born
with this congenital defect. Find out how HRGN is working to
answer this unmet medical need.
Esophageal Atresia
Esophageal Atresia:
A Life-Threatening Condition that Demands Effective Treatment
Approximately 1 in 4,000 babies, in the US alone, are bornwith this congenital defect. Find out how HRGN is working to
answer this unmet medical need.
Esophageal Atresia
Esophageal Atresia:
A Life-Threatening Condition that Demands Effective Treatment
Approximately 1 in 4,000 babies, in the US alone, are bornwith this congenital defect. Find out how HRGN is working to
answer this unmet medical need.
Esophageal Atresia
Esophageal Atresia:
A Life-Threatening Condition that Demands Effective Treatment
Approximately 1 in 4,000 babies, in the US alone, are bornwith this congenital defect. Find out how HRGN is working to
answer this unmet medical need.